IP Verse

Use Of Hif Alpha Stabilizers For Enhancing Erythropoiesis - EP2322153

The patent EP2322153 was granted to Fibrogen on Oct 8, 2014. The application was originally filed on Jun 4, 2004 under application number EP10182213A. The patent is currently recorded with a legal status of "Revoked".

EP2322153

FIBROGEN
Application Number
EP10182213A
Filing Date
Jun 4, 2004
Status
Revoked
Jun 10, 2022
Grant Date
Oct 8, 2014
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEJun 26, 2019KNIGHTWITHDRAWN
BAYER GMBHBAYER PHARMA AKTIENGESELLSCHAFTBAYER ANIMAL HEALTHJul 8, 2015VON RENESSEWITHDRAWN
AKEBIA THERAPEUTICSJul 6, 2015JONES DAYADMISSIBLE
GLAXO GROUPJul 6, 2015KNIGHTWITHDRAWN

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0650960
DESCRIPTIONEP0650961
DESCRIPTIONUS5607954
DESCRIPTIONUS5610172
DESCRIPTIONUS5620995
DESCRIPTIONUS5620996
DESCRIPTIONUS5658933
DESCRIPTIONUS5719164
DESCRIPTIONUS5726305
DESCRIPTIONUS5942434
DESCRIPTIONUS6020350
DESCRIPTIONUS6093730
DESCRIPTIONUS6124131
DESCRIPTIONUS6432927
DESCRIPTIONUS6562799
DESCRIPTIONWO0050390
DESCRIPTIONWO0069908
DESCRIPTIONWO03045440
DESCRIPTIONWO03049686
DESCRIPTIONWO03053977
DESCRIPTIONWO03053997
EXAMINATIONWO03053997
OPPOSITIONEP1633333
OTHERWO03053997
SEARCHWO03049686

Non-Patent Literature (NPL) Citations (119) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BEVILACQUA ET AL., PROC NATL ACAD SCI USA, (1987), vol. 84, pages 9238 - 9242-
DESCRIPTION- BEVILACQUA; VAN FURTH, J LEUKOC BIOL, (1993), vol. 54, pages 363 - 378-
DESCRIPTION- BICKEL ET AL., HEPATOLOGY, (1998), vol. 28, pages 404 - 411-
DESCRIPTION- BOTTOMLEY; MULLER-EBERHARD, SEMIN HEMATOL, (1988), vol. 25, pages 282 - 302-
DESCRIPTION- BRUICK; MCKNIGHT, SCIENCE, (2001), vol. 294, pages 1337 - 1340-
DESCRIPTION- CANONNE-HERGAUX ET AL., BLOOD, (1999), vol. 93, pages 4406 - 4417-
DESCRIPTION- CLIBON ET AL., EXP HEMATOL, (1990), vol. 18, pages 438 - 441-
DESCRIPTION- COLOWICK, S. ET AL.,, Methods In Enzymology, ACADEMIC PRESS, INC.-
DESCRIPTION- CUNLIFFE ET AL., BIOCHEM J, (1986), vol. 240, pages 617 - 619-
DESCRIPTION- DUPUY ET AL., GENOMICS, (2000), vol. 69, pages 348 - 54-
DESCRIPTION- EPSTEIN ET AL., CELL, (2001), vol. 107, pages 43 - 54-
DESCRIPTION- FRANKLIN, BIOCHEM SOC TRANS, (1991), vol. 19, page 812 815-
DESCRIPTION- FRANKLIN ET AL., BIOCHEM J, (2001), vol. 353, pages 333 - 338-
DESCRIPTION- FRIEDMAN ET AL., PROC NATL ACAD SCI USA, (2000), vol. 97, pages 4736 - 4741-
DESCRIPTION- FUCHS ET AL., EUR J HEMATOL, (1991), vol. 46, pages 65 - 70-
DESCRIPTION- GOCH ET AL., EUR J HEMATOL, (1995), vol. 55, pages 73 - 77-
DESCRIPTION- GOSWAMI ET AL., BIOCHEM CELL BIOL, (2002), vol. 80, pages 679 - 689-
DESCRIPTION- GUNSHIN ET AL., FEBS LETT, (2001), vol. 509, pages 309 - 316-
DESCRIPTION- HAILE, AM J MED SCI, (1999), vol. 318, pages 230 - 240-
DESCRIPTION- Handbook of Experimental Immunology, BLACKWELL SCIENTIFIC PUBLICATIONS, (1986), vol. I-IV-
DESCRIPTION- HANSON ET AL., J BIOL CHEM, (1999), vol. 274, pages 5047 - 5052-
DESCRIPTION- HIRSILA ET AL., J BIOL CHEM, (2003), vol. 278, pages 30772 - 30780-
DESCRIPTION- IVAN; KAELIN, SCIENCE, (2001), vol. 292, pages 464 - 468-
DESCRIPTION- IVAN, SCIENCE, (2001), vol. 292, pages 464 - 468-
DESCRIPTION- JELKMANN ET AL., ANN NY ACAD SCI, (1991), vol. 718, pages 300 - 311-
DESCRIPTION- JELKMANN ET AL., ANN NY ACAD SCI, (1994), vol. 718, pages 300 - 311-
DESCRIPTION- JIA ET AL., PROC NATL ACAD SCI USA, (1994), vol. 91, pages 7227 - 7231-
DESCRIPTION- JIANG ET AL., J BIOL CHEM, (1997), vol. 272, pages 19253 - 19260-
DESCRIPTION- KAULE; GUNZLER, ANAL BIOCHEM, (1990), vol. 184, pages 291 - 297-
DESCRIPTION- KIVIRIKKO; MYLLYHARJU, MATRIX BIOL, (1998), vol. 16, pages 357 - 368-
DESCRIPTION- KLAUSNER ET AL., CELL, (1993), vol. 72, pages 19 - 28-
DESCRIPTION- LIN ET AL., PROC NATL ACAD SCI USA, (1985), vol. 82, pages 7580 - 7584-
DESCRIPTION- MACDOUGALL; COOPER, NEPROL DIAL TRANSPLANT, (2002), vol. 17, no. 11, pages 39 - 43-
DESCRIPTION- MAJAMAA ET AL., BIOCHEM J, (1985), vol. 229, pages 127 - 133-
DESCRIPTION- MAJAMAA ET AL., BIOCHEM J, vol. 229, pages 127 - 133-
DESCRIPTION- MAJAMAA ET AL., EUR J BIOCHEM, (1984), vol. 138, pages 239 - 245-
DESCRIPTION- MCKIE ET AL., SCIENCE, (2001), vol. 291, pages 1755 - 1759-
DESCRIPTION- MEANS, 7NT J HEMATOL, (1999), vol. 70, pages 7 - 12-
DESCRIPTION- MEANS, INT J HEMATOL, (1999), vol. 70, pages 7 - 12-
DESCRIPTION- MEANS, STEM CELLS, (1995), vol. 13, pages 32 - 37-
DESCRIPTION- Molecular Cloning: A Laboratory Manual, 2nd edition, COLD SPRING HARBOR LABORATORY PRESS, (1989), vol. 1-HI-
DESCRIPTION- MYLLYHARJU; KIVIRIKKO, EMBO J, (1997), vol. 16, pages 1173 - 1180-
DESCRIPTION- OLDENBURG ET AL., ALIMENT PHARMACOL THER, (2001), vol. 15, pages 429 - 438-
DESCRIPTION- PALMERINI ET AL., J CHROMATOGR, (1985), vol. 339, pages 285 - 292-
DESCRIPTION- PROC NATL ACAD SCI USA, (2002), vol. 99, pages 13459 - 13464-
DESCRIPTION- ROODMAN ET AL., ADV EXP MED BIOL, (1989), vol. 271, pages 185 - 196-
DESCRIPTION- SALVARANI ET AL., RHEUMATOL INT, (1996), vol. 16, pages 45 - 48-
DESCRIPTION- SARTOR ET AL., INFECTION AND IMMUNITY, (1989), vol. 57, pages 1177 - 1185-
DESCRIPTION- SRINIVAS ET AL., BIOCHEM BIOPHYS RES COMMUN, (1999), vol. 260, pages 557 - 561-
DESCRIPTION- TAYLOR, GENE, (2001), vol. 275, pages 125 - 132-
DESCRIPTION- TRAN ET AL., J NUTR, (2002), vol. 132, pages 351 - 356-
DESCRIPTION- VANNUCCHI ET AL., BR J HEMATOL, (1994), vol. 87, pages 18 - 23-
DESCRIPTION- YIN ET AL., BLOOD, CELLS, MOLECULES, AND DISEASES, (1998), vol. 24, no. 3, pages 41 - 533-
OPPOSITION- AKIZAWA T et al., "Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects", Am. J. Nephrol., (20170000), vol. 45, pages 127 - 135-
OPPOSITION- Allan J. Erslev, "Anemia of Chronic disease", Anemia of Chronic disease, (20010000), pages 481 - 487, XP055619098-
OPPOSITION- ANG, S. O. et al., "Von Hippel-Lindau Protein, Chuvash Polycythemia and Oxygen Sensing", Blood, (20010000), vol. 98, no. 11, page 748a, XP055453005-
OPPOSITION- ARIAZI et al., "Discovery and Preclinical Characterisation of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia", J Pharmacol Exp Ther, (20170000), vol. 363, no. 3, pages 336 - 347, XP055619105-
OPPOSITION- BEUTLER, "Production and Destruction of Erythrocytes", Williams Hematology, (20010000), pages 355 - 368-
OPPOSITION- BOTHWELL et al., "Erythrokinetics IV The Plasma Iron Turnover as a Measure of Erythropoiesis", Blood, (19570000), vol. XII, no. 5, pages 409 - 427, XP055453032-
OPPOSITION- CANNONE-HERGAUX et al., "Cellular and Subcellular Localization of the Nramp2 Iron Transporter in the Intestinal Brush Border and Regulation by Dietary Iron", Blood, (19990000), vol. 93, no. 12, pages 4406 - 4417, XP055619152-
OPPOSITION- CANTRILL et al., "Iron Absorption from the Intestinal Tract: The Influence of the Haemoglobin Concentration and of Hypoxia, Austral", J Exp Biol, (19620000), vol. 40, pages 31 - 36-
OPPOSITION- CAVILL et al., "Correspondence: Functional Iron Deficiency", Blood, (19930000), vol. 82, no. 4, page 1377-
OPPOSITION- "Chapter 139", H. DAVID HUMES, Kelley's Essentials of Internal Medicine. 2nd ed., Lippincott Williams and Wilkins, (20010000), pages 510 - 511, XP055366950-
OPPOSITION- CHUNG et al., "Molecular mechanisms of iron regulation of siderophore systems in gram negative bacteria", Critical Reviews in Clinical Laboratory Sciences, (20030000), vol. 40, no. 2, pages 151 - 182, XP027309956-
OPPOSITION- COLEHOUR, J. K. et al., "Effect of Hypoxia on Serum Iron and the Unsaturated Iron-Binding Capacity of Serum in Rats", Am. J. Physiol., (19570000), vol. 191, no. 1, pages 113 - 114, XP055452990-
OPPOSITION- FAIRBANKS et al., "Iron Deficiency", Williams Hematolog y, (20010000), vol. 38, pages 447 - 470-
OPPOSITION- FAIRBANKS et al., "Iron Metabolism", Williams Hematology, (20010000), vol. 24, pages 295 - 304-
OPPOSITION- FLEMING et al., "Microcytic anaemia mice has a mutation in Nramp2, a candidate iron transporter gene", Nature Genetics, (19970000), vol. 16, pages 383 - 386, XP055619151-
OPPOSITION- HATHORN, M. K. S., "The Influence of Hypoxia on Iron Absorption in the Rat", Gastroenterology, (19710000), vol. 60, no. 1, pages 76 - 81, XP055452980-
OPPOSITION- HUEBERS et al., "The Physiology of Transferrin and Transferrin Receptors", Physiological Reviews, (19870000), vol. 67, no. 2, ISSN 10.1152/physrev.1987.67.2.520, pages 520 - 582-
OPPOSITION- LAWRENCE, J. H. et al., "A physiological study in the Peruvian andes", Acta Medica Scandinavica, (19520000), vol. CXLII, no. II, pages 117 - 131, XP055453011-
OPPOSITION- MAZUR, A. et al., "The mechanism of iron release from ferritin as related to its biological properties", J. Biol. Chem., (19550000), vol. 213, pages 147 - 160, XP055453021-
OPPOSITION- MEBERG, A. et al., "Smoking during pregnancy - hematological observations in the newborn", Acta Paediatr Scand, (19790000), vol. 68, pages 291 - 292, XP055453016-
OPPOSITION- MENDEL, "Studies on Iron Absortion. I The Relationships between the Rate of Erythropoiesis, Hypoxia and Iron Absorption", Blood, (19610000), vol. 18, pages 727 - 736, XP055619142-
OPPOSITION- MORGAN, E. H., "Effect of Hypoxia on serum concentration of transferrin and other serum proteins in human subjects", J. Lab. Clin. Med., (19700000), vol. 75, no. 6, pages 1006 - 1012, XP055452968-
OPPOSITION- NEMETH et al., "IL-6 mediates hypoferremia of inflammation by infucing the synthesis of the iron regulatory hormone hepcidin", The Journal of Clinical Investigation, (20040000), vol. 113, no. 9, pages 1271 - 1276, XP055619212-
OPPOSITION- Ratcliffe, "From Erythropoietin to Oxygen: Hypoxia-Inducible Factor Hydroxylases and the Hypoxia Signal Pathway", Blood, (20020000), vol. 20, pages 445 - 450-
OPPOSITION- ROBINSON et al., "The effect of oral therapy with cobaltous chloride on the blood of patients suffering with chronic supperative infection", New Engl. J. Med., (19490000), vol. 240, no. 19, pages 749 - 753, XP055366949-
OPPOSITION- ROBINSON et al., "The effect of oral therapy with cobaltous chloride on the blood of patients suffering with chronic supperative infection", The New England Journal of Medicine, (19490512), vol. 240, no. 19, pages 749 - 753, XP055366949-
OPPOSITION- SCHULZ, E. et al., "Investigations on Latent Erythropoietin (ESF) Deficiency in non- Anaemic Patients with Chronic Renal Disease Using Hypoxic Stimulation Methods", Klin. Wschr., (19780000), vol. 56, pages 337 - 340, XP055452984-
OPPOSITION- SCHULZ, E. et al., "Investigations on Latent Erythropoietin (ESF) Deficiency in non-Anaemic Patients with Chronic Renal Disease Using Hypoxic Stimulation Methods", Klin. Wschr., (19780000), vol. 56, pages 337 - 340, XP055452984-
OPPOSITION- SEMENZA, "HIF-1 and human disease: one highly involved factor", Genes Dev, (20000000), vol. 14, pages 1983 - 1991, XP002242169-
OPPOSITION- SIMPSON, R. J., "Effect of hypoxic exposure on iron absorption in heterozygous hypotransferrinaemic mice", Ann. Hematol, (19920000), vol. 65, pages 260 - 264, XP055452973-
OPPOSITION- SIMPSON, R. J., "Effect of hypoxic exposure on iron absorption in heterozygous hypotransferrinaemic mice", Ann. Hematol., (19920000), vol. 65, pages 260 - 264, XP055452973-
OPPOSITION- VASSAR et al., "Effects of hypoxia on iron absorption in rats", Proc. Soc. Exp. Biol. Med., (19560000), vol. 93, no. 3, pages 504 - 506-
OPPOSITION- WICK et al., "Clinical Aspects and Laboratory, Iron Metabolism Anemias", Novel concepts in the anemias of malignancies and renal and rheumatoid diseases, (20030200), pages 1 - 219, XP055618551-
OPPOSITION- LEE et al., "The Human Nramp2 Gene : Characterisation of the Gene Structure, Alternative Splicing, Promoter Region and Polymorphisms", Blood, Cells, Molecules and Diseases, (19980000), vol. 24, no. 9, pages 199 - 215, XP004635549
OPPOSITION- PERGOLA PE et al., "Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease", Kidney International, (20160000), vol. 90, no. 5, doi:10.1016/j.kint.2016.07.019, pages 1115 - 1122, XP055619130
OPPOSITION- MCKIE et al., "A Novel Duodenal Iron Regulated Transporter, IREG1, Implicated in the Basolateral Transfer of Iron to the Circulation", Molecular Cell, (20000000), vol. 5, doi:doi:10.1016/S1097-2765(00)80425-6, pages 299 - 309, XP002523045
OPPOSITION- SEMENZA, "Hypoxia inducible factor 1: oxygen homeostasis and disease pathophysiology", Trends Mol Med, (20010000), vol. 7, no. 8, doi:doi:10.1016/S1471-4914(01)02090-1, pages 345 - 350, XP002338429
OPPOSITION- DONOVAN et al., "Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter", Nature, (20000000), vol. 403, doi:doi:10.1038/35001596, pages 776 - 781, XP002310808
OPPOSITION- VULPE et al., "Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport , is defective in the sla mouse", Nature Genetics, (19990000), vol. 21, doi:doi:10.1038/5979, pages 195 - 199, XP002210151
OPPOSITION- Ugo Testa, "Recent developments in the understanding of iron metabolism", The Hematology Journal, (20020000), vol. 3, no. 2, pages 63 - 89, XP055619219
OPPOSITION- BRIGANDI RA et al., "A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial", Am J Kidney Dis, (20160000), vol. 67, no. 6, doi:doi:10.1053/j.ajkd.2015.11.021, pages 861 - 871, XP029552382
OPPOSITION- PROVENZANO R et al., "Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study", Am. J. Kidney. Dis., (20160000), vol. 67, no. 6, doi:doi:10.1053/j.ajkd.2015.12.020, pages 912 - 924, XP029552387
OPPOSITION- HUANG et al., "Regulation of hypoxia-inducible factor 1 a is mediated by an 02 dependent degradation domain via the ubiquitin-proteasome pathway", Proc. Natl. Acad. Sci., USA, (19980000), vol. 95, doi:doi:10.1073/pnas.95.14.7987, pages 7987 - 7992, XP002145581
OPPOSITION- HARRIS et al., "Targeted gene disruption reveals and essential role for ceruloplasmin in cellular iron efflux", Proc. Natl. Acad. Sci., USA, (19990000), vol. 96, no. 19, pages 10812 - 10817, XP055619155
OPPOSITION- LOK et al., "Identification of a Hypoxia Response Element in the Transferrin Receptor Gene", J. Biol. Chem., (19990000), vol. 274, no. 34, pages 24147 - 24241, XP055111789
OPPOSITION- ABBOUD et al., "A Novel Mammalian Iron Regulated Protein involved in Intracellular Iron Metabolism", The Journal of Biological Chemistry, (20000000), vol. 275, no. 26, doi:doi:10.1074/jbc.M000713200, pages 19906 - 19912, XP002219402
OPPOSITION- HOLDSTOCK L et al., "Daprodustat for anemia: a 24- week, open-label, randomized controlled trial in participants with chronic kidney disease", Clinical Kidney Journal, (20180000), vol. 12, no. 1, doi:10.1093/ckj/sfy013, pages 129 - 138, XP055619113
OPPOSITION- MEADOWCROFT A et al., "Daprodustat for anemia: a 24 week, open-label, randomized controlled trial in participants on hemodialysis", Clinical Kidney Journal, (20190000), vol. 12, no. 1, doi:10.1093/ckj/sfy014, ISSN 2048-8505, pages 139 - 148, XP055619111
OPPOSITION- TRAN et al., "Dietary Iron Status has little effect on expression of Ceruloplasmin but alters that of Ferritin in rats", J. Nutr., (20020000), vol. 132, no. 3, doi:10.1093/jn/132.3.351, ISSN 0022-3166, pages 351 - 356, XP055619214
OPPOSITION- BESARAB A et al., "Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CDK) patients", Nephrol. Dial. Transplant, (20150000), vol. 30, no. 10, doi:10.1093/ndt/gfv302, ISSN 0931-0509, pages 1665 - 1673, XP055619124
OPPOSITION- CHEN N et al., "Phase 2 studies of oral hypoxia- inducible factor prolyl hydroxylase inhibitor FG- 4592 for treatment of anemia in China", Nephrol. Dial. Transplant., (20170000), vol. 32, no. 8, doi:10.1093/ndt/gfx011, ISSN 0931-0509, pages 1373 - 1386, XP055619128
OPPOSITION- MCKIE et al., "An Iron Regulated Ferric Reductase Associated with the Absorption of Dietary Iron", Science, (20010000), vol. 291, no. 5509, doi:10.1126/science.1057206, pages 1755 - 1759, XP055619146
OPPOSITION- JANOFF, A. et al., "Levels of plasma-bound iron in experimental shock in the rabbit and dog", Am J. Physiol., (19600000), vol. 198, no. 6, doi:doi:10.1152/ajplegacy.1960.198.6.1161, pages 1161 - 1165, XP055453019
OPPOSITION- JANOFF, A. et al., "Levels of plasma-bound iron in experimental shock in the rabbit and dog", Am J. Physiol., (19600000), vol. 198, no. 6, pages 1161 - 1165, XP055453019
OPPOSITION- JANDL et al., "The Plasma to Cell Cycle of Transferrin", Journal of Clinical Investigation, (19630000), vol. 42, no. 3, doi:10.1172/JCI104718, pages 314 - 326, XP055619157
OPPOSITION- NICOLAS et al., "The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation", J. Clin. Invest., (20020000), vol. 110, no. 7, doi:10.1172/JCI0215686, ISSN 0021-9738, pages 1037 - 1044, XP002356756
OPPOSITION- HOFER et al., "Hypoxic up-regulation of erythroid 5- aminolevulinate synthase", Blood, (20030000), vol. 101, no. 1, doi:doi:10.1182/blood-2002-03-0773, pages 348 - 350, XP055111792
OPPOSITION- NEMETH et al., "Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein", Blood, (20030000), vol. 101, no. 7, doi:doi:10.1182/blood-2002-10-3235, pages 2461 - 2463, XP002356755
OPPOSITION- CANNONE HERGAUX et al., "Expression of the DMT1 (NRAMP2/DCT1) iron transporter in mice with genetic iron overload disorders", Blood, (20010000), vol. 97, no. 4, pages 1138 - 1140, XP055619154
OPPOSITION- ROY et al., "2002 E Mead Johnson Award for Research in Pediatrics Lecture: The Molecular Biology of the Anemia of Chronic Disease: A Hypothesis", Pediatric Res., (20030000), vol. 53, no. 3, doi:10.1203/01.PDR.0000049513.67410.2D, pages 507 - 512, XP055619106
OPPOSITION- HOLDSTOCK L et al., "Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia", J. Am. Soc. Nephrol., (20150000), vol. 27, no. 4, pages 1234 - 1244, XP055619120
OPPOSITION- BESARAB et al., "Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients", J Am Soc Nephrol, (20160000), vol. 27, no. 4, pages 1225 - 1233, XP055619108
OPPOSITION- MYLLYHARJU, "HIF prolyl-4-hydroxylases and their potential as drug targets", current Pharmaceutical Design, (20090000), vol. 15, doi:doi:10.2174/138161209789649457, pages 3878 - 3885, XP003033497
OTHER- IVAN M; ET AL, "BIOCHEMICAL PURIFICATION AND PHARMACOLOGICAL INHIBITION OF A MAMMALIAN PROLYL HYDROXYLASE ACTING ON HYPOXIA-INDUCIBLE FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,, (20021015), vol. 99, no. 21, pages 13459 - 13465, XP002232952
OTHER- J. MYLLYHARJU, "HIF PROLYL 4-HYDRIXYLASES AND THEIR POTENTIAL AS DRUG TARGETS", CURRENT PHARMACEUTICAL DESIGN, (2009), vol. 15, pages 3878 - 3885, XP003033497
SEARCH- SALVARANI C ET AL, "Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis", RHEUMATOLOGY INTERNATIONAL, (1996), vol. 16, no. 2, ISSN 0172-8172, pages 45 - 48, XP009037762 [X] 1-14,18 * page 47 - page 48 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents